PTC Therapeutics Revenue, Profits - PTCT Quarterly Income Statement

Add to My Stocks
$46.31 $0.94 (2.07%) PTCT stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the PTC Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. Like any other income statement, the PTCT income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue growth of 22.62% when compared to the same period in the past. Revenue for year 2018 Q2 is $68.74M and has increased from $56.06M quarter on quarter as is evident when you compare the latest figures in the latest PTC Therapeutics profit and loss statement with those of the prior corresponding period. Also see PTC Therapeutics assets and PTC Therapeutics free cash flow for a complete valuation of PTCT stock.

View and download details of revenue and profits for PTC Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
PTC Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)2.57M3.04M2.21M1.58M------
PTC Therapeutics Gross Profit
Research & Development Expense32.61M31.36M29.24M30.02M30.83M27.36M26.03M31.39M28.82M31.39M
Selling General & Admin Expense33.55M32.96M35.49M31.42M28.86M25.5M24.19M23.65M23.36M25.93M
Income Before Depreciation Depletion Amortization--11.31M11.1M-21.17M-12.49M-26.35M-24.99M-32.06M-36.56M-38.44M
Depreciation Depletion Amortization5.59M5.42M5.67M9.71M------
Non Operating Income-0.67M1M---1.82M-0.31M-3.59M-0.78M-2.44M-2.67M
Interest Expense2.88M3.3M3.46M3.42M3M2.21M-2.13M2.13M--
PTC Therapeutics Pretax Income
Provision for Income Taxes---------0.09M-
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-9.52M-19.26M1.27M-33.74M-17.48M-29.06M-26.8M-35.17M-38.91M-41.23M
Extraordinary Items & Discontinued Operations----------
PTC Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS46.14M41.63M41.97M41.3M39.62M34.31M34.17M34.09M34M33.92M
Average Shares used to compute Basic EPS46.14M41.63M41.35M41.3M39.62M34.31M34.17M34.09M34M33.92M
Income Before Nonrecurring Items-3.93M-19.26M1.27M-27.42M-17.48M-29.06M-26.8M-35.17M-38.91M-39.33M
Income from Nonrecurring Items-5.59M---6.32M------1.9M
PTC Therapeutics Earnings Per Share Basic Net
PTC Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.09-0.460.03-0.67-0.44-0.85-0.78-1.03-1.14-1.16
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

PTC Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: PTC Therapeutics revenue chart, implies that the company is growing. It has been the case with PTC Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-9.52M for PTCT stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The PTCT financials along with PTC Therapeutics historical stock prices provide a lot of details about the firm.

PTC Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield